Today Halozyme Therapeutics and Pfizer announced that they will be partnering in order to create a subcutaneous drug. Halozyme will be licensing their Enhanze technology to Pfizer, which will help to increase the amount of medication that is absorbed, making the treatment more efficient.
Halozyme's Enhanze technology is used to allow intravenous biologic vaccines and drugs to be received subcutaneously by patients, reducing treatment length and improving convenience. For some therapies, subcutaneous injections can allow patients to self-administer the drugs rather than go to the hospital, potentially lowering health-care costs. The technology is also used to improve the effectiveness of drugs that are currently received subcutaneously.
With so many drugs expiring, how will these collaborations effect the future of the Pharma industry?
These days Pharmaceutical companies live and die by their ability to collaborate effectively. With so many different opportunities out there, where do you begin? Craig Sorensen, Vice President,R&D Alliance Design and Management, VERTEX PHARMACEUTICALS and Andy Donnelly, Associate Director, Drug Delivery and Device Development, Formulation Sciences, MEDIMMUNE answer all your questions during our session, Structure Pharmaceutical Collaborations to Maximize Use of New Technologies.
To learn more about the Drug Delivery Partnerships event, check out our agenda and join us February 6-8 in San Diego, Ca! As a reader of the Drug Delivery Partnerships International blog, you get a 15% discount off the standard rate when using code XP1878BLOG to register here.
No comments:
Post a Comment